Insulin Glargine Induces Less Insulin Antibody Than Other Insulin Regimens

In this cross-sectional, retrospective study, the researchers included 1863 patients with T2DM who were using exogenous insulin therapy. They included patients who had stable antidiabetic therapy in the last 3 months and measured IA levels using the iodine-125 array. Among 1863 patients, 902 (48.4%) patients had positive IAs (IA level >5%).

Key findings of the study:

• Upon analysis, the researchers found that IA level was positively correlated with fasting blood glucose (OR=1.069).
• They also found that the proportion of positive IAs was lowest in patients using glargine only (31.9%) and highest in patients using human insulin only (70.3%).
• They noted that the IA levels in patients using sulfonylureas/glinides (8.3 %), metformin (9.6 %), and DPP-4 inhibitors (8.2 %) were all lower than in patients without these drugs.

The authors concluded, "IA levels should be tested in patients with T2DM who are using insulin therapy, especially in elderly non-smokers with lipid metabolic disorder. The use of insulin glargine, DPP-4 inhibitors, metformin, insulin secretagogues, and SGLT2 inhibitors were associated with lower IA levels, which may be considered in patients with T2DM who need insulin therapy, especially those who had positive IAs. The causal relationships between changes of IA levels and these drugs need further study."

For further information:

DOI:10.21203/rs.3.rs-1345032/v1

Keywords:

insulin antibodies, insulin therapy, glucose-lowering drugs, glargine, DPP-4 inhibitors, metformin, insulin secretagogues, SGLT2 inhibitors, type 2 diabetic mellitus, Research Square, Peng Zhang